dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Barbour, Thomas |
dc.contributor.author | Scully, Marie |
dc.contributor.author | Cataland, Spero |
dc.contributor.author | Garlo, Katherine |
dc.contributor.author | Heyne, Nils |
dc.contributor.author | Ariceta Iraola, Gema |
dc.date.accessioned | 2022-03-21T09:06:30Z |
dc.date.available | 2022-03-21T09:06:30Z |
dc.date.issued | 2021-03-24 |
dc.identifier.citation | Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, et al. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Reports. 2021 Mar 24;6(6):1603–13. |
dc.identifier.issn | 2468-0249 |
dc.identifier.uri | https://hdl.handle.net/11351/7217 |
dc.description | Síndrome hemolítico urémico; Insuficiencia renal; Ravulizumab |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Kidney International Reports;6(6) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Síndrome hemolíticourèmica - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Malalties rares |
dc.subject.mesh | Atypical Hemolytic Uremic Syndrome |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.subject.mesh | Rare Diseases |
dc.title | Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ekir.2021.03.884 |
dc.subject.decs | síndrome hemolítico urémico atípico |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.subject.decs | enfermedades raras |
dc.relation.publishversion | https://doi.org/10.1016/j.ekir.2021.03.884 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Barbour T] Kidney Care, The Royal Melbourne Hospital, Melbourne, Australia. [Scully M] Department of Haematology, University College London Hospitals, London, UK. [Ariceta G] Servei de Nefrologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cataland S] Division of Hematology, The Ohio State University Medical Center, Columbus, Ohio, USA. [Garlo K] Clinical Development, Alexion Pharmaceuticals, Inc., Boston, Massachusetts, USA. [Heyne N] Section of Nephrology and Hypertension, Tübingen University Hospital, Tübingen, Germany |
dc.identifier.pmid | 34169200 |
dc.identifier.wos | 000661053500016 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |